News Conference News AHA 2018 Complications Following TAVR Are Going Down, US Data Show Yael L. Maxwell November 20, 2018
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News AHA 2018 Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF Todd Neale November 11, 2018
News Conference News TCT 2018 More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses Michael O'Riordan September 24, 2018
News Conference News ESC 2018 My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More Shelley Wood September 14, 2018
News Conference News ESC 2018 COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure Todd Neale August 27, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ACC 2018 COMPASS Approach Helps With Leg Complications in Patients With PAD Todd Neale March 12, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2018 Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis Todd Neale March 12, 2018
News Conference News CRT 2018 Ticagrelor: Better Platelet Blockade Post-TAVR? Michael O'Riordan March 07, 2018
News Conference News ISC 2018 More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs Todd Neale January 27, 2018
News Conference News ISC 2018 COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke Todd Neale January 25, 2018